Vor Biopharma Inc. (VOR)
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Vor Biopharma Inc.
NASDAQ:VORHealthcare · Biotechnology
-5.88%$19.68
AH$19.75+0.36%vs close
Mkt Cap$1.21B
Float42.24M
O/S61.43M
Vol
$ Vol
RVOL
Inst Own79.0%
SI17.6%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$695.98M
Total Assets$464.13M
Free Cash Flow-$143.65M
Debt & Equity
Total Debt$3M
Total Equity-$164.31M
Shares Outstanding
Short Interest
Split History1 split · 1 reverse
2-year cumulative
1:20
Nasdaq bars a compliance period at 1:250
- 1:20Reverse splitSep 19, 202520 shares → 1
Balance Sheet Details
Assets$464.13M
Liabilities$628.44M
Accounts Receivable$0
Accounts Payable$5.13M
Inventory$0
PP&E (Net)$3.47M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - | - |
| Cost of Revenue | $0 | $0 | $3.49M | $8.96M | $0 | $0 | $91K | $20K |
| Gross Profit | $0 | $0 | -$3.49M | -$8.96M | $0 | $0 | -$91K | -$20K |
| Gross Margin | - | - | - | - | - | - | - | - |
| Research and Development | $321.53M | $93.31M | $94.31M | $64.55M | $47.53M | $31.62M | $6.2M | $2.43M |
| Selling, General, and Administrative | $50.11M | $27.88M | $31.72M | $19.91M | $21.49M | $11.75M | $4.13M | $427K |
| Other | $0 | $0 | -$3.49M | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $371.64M | $121.19M | $122.54M | $84.46M | $69.02M | $43.37M | $10.33M | $2.86M |
| Operating Income (EBIT) | -$371.64M | -$121.19M | -$126.04M | -$93.42M | -$69.02M | -$43.37M | -$10.42M | -$2.86M |
| Operating Margin | - | - | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $0 | $608K | $1M |
| Interest Income | $5.87M | $4.27M | $8.17M | $1.32M | $119K | $29K | $154K | $0 |
| Other Income (Expense) | -$324.34M | $4.27M | $8.17M | $1.32M | $119K | $29K | -$422K | -$1.29M |
| Income Before Tax (EBT) | -$695.98M | -$116.91M | -$117.86M | -$92.09M | -$68.9M | -$43.34M | -$10.84M | -$4.15M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$695.98M | -$116.91M | -$117.86M | -$92.09M | -$68.9M | -$43.34M | -$10.84M | -$4.15M |
| Net Income Margin | - | - | - | - | - | - | - | - |
| Supplementary Data | ||||||||
| EPS | -70.50 | -34.00 | -35.00 | -46.60 | -37.80 | -26.60 | -6.20 | -14.60 |
| Diluted EPS | -70.50 | -34.00 | -35.00 | -46.60 | -37.80 | -26.60 | -6.20 | -14.60 |
| Weighted Average OS | 9.87M | 3.44M | 3.36M | 1.98M | 1.86M | 1.86M | 1.86M | 283,024 |
| EBITDA | -$693.09M | -$113.39M | -$114.37M | -$89.57M | -$67.47M | -$42.76M | -$10.14M | -$2.84M |
| EBITDA Margin | - | - | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and Cash Equivalents | $396.49M | $81.95M | $31.36M | $57.71M | $119.8M | $48.54M | $6.47M | $929K |
| Short-Term Investments | $58.72M | $9.98M | $105.81M | $172.54M | $87.67M | $0 | $0 | $0 |
| Cash and Short-Term Investments | $455.21M | $91.93M | $137.18M | $230.25M | $207.47M | $48.54M | $6.47M | $929K |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $1.75M | $380K | $475K | $2.34M | $2.09M | $100K | $205K | $0 |
| Total Current Assets | $458.11M | $96.51M | $140.8M | $236.95M | $214.4M | $49.11M | $7.54M | $936K |
| Long-Term Assets | ||||||||
| Property, Plant & Equipment Net | $3.47M | $41.59M | $50.1M | $57.08M | $22.52M | $21.84M | $728K | $71K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $2.41M | $2.41M | $0 | $1.56M | $1.56M | $0 |
| Deferred Tax Assets | $0 | $0 | $11.7M | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $2.55M | $4.8M | $4.81M | $2.92M | $5.67M | $3.4M | $0 | $0 |
| Total Long-Term Assets | $6.02M | $46.38M | $69.03M | $62.42M | $28.19M | $26.8M | $2.29M | $71K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $464.13M | $142.89M | $209.83M | $299.37M | $242.59M | $75.91M | $9.83M | $1.01M |
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | $5.13M | $1.5M | $815K | $1.77M | $1.54M | $2.36M | $693K | $38K |
| Short-Term Debt | $280K | $0 | $3.83M | $0 | $0 | $863K | $0 | $4.46M |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.4M |
| Other Current Liabilities | $15.33M | $6.21M | $4.96M | $4.95M | $434K | $4.26M | $900K | $3.19M |
| Total Current Liabilities | $25.17M | $18.61M | $15.57M | $13.12M | $10.15M | $10.21M | $2.19M | $7.77M |
| Long-Term Liabilities | ||||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $11.7M | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $600.55M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Liabilities | $603.27M | $27.61M | $43.53M | $35.64M | $16.17M | $17.43M | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $628.44M | $46.23M | $59.1M | $48.76M | $26.33M | $27.64M | $2.19M | $7.77M |
| Stockholders' Equity | ||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $107.34M | $25.07M | $2K |
| Common Stock | $18K | $13K | $7K | $7K | $4K | $1K | $0 | $0 |
| Retained Earnings | -$1.15B | -$456.99M | -$340.08M | -$222.22M | -$130.12M | -$61.22M | -$17.89M | -$7.05M |
| Comprehensive Income & Other | $41K | $22K | -$77K | -$770K | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $988.64M | $553.64M | $490.8M | $472.82M | $346.38M | $109.49M | $25.53M | $281K |
| Total Equity | -$164.31M | $96.66M | $150.72M | $250.61M | $216.26M | $48.27M | $7.64M | -$6.77M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $464.13M | $142.89M | $209.83M | $299.37M | $242.59M | $75.91M | $9.83M | $1.01M |
| Supplementary Data | ||||||||
| Total Debt | $3M | $31.83M | $35.66M | $38.91M | $18.01M | $18.29M | $0 | $4.46M |
| Net Debt | -$393.49M | -$50.12M | $4.3M | -$18.79M | -$101.79M | -$30.25M | -$6.47M | $3.53M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Operating Activities | ||||||||
| Net Income | -$695.98M | -$116.91M | -$117.86M | -$92.09M | -$68.9M | -$43.34M | -$10.84M | -$4.15M |
| Depreciation & Amortization | $2.89M | $3.53M | $3.49M | $2.52M | $1.43M | $605K | $91K | $20K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $289K |
| Stock-Based Compensation | $18.91M | $9.85M | $13.36M | $10.7M | $4.32M | $1.34M | $172K | $116K |
| Changes in Working Capital: | ||||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $0 | $2.24M | $2.85M | $0 | $405K | $0 | $0 | $65K |
| Other Working Capital | $10.21M | -$2.24M | -$2.2M | -$12.69M | -$9.59M | $4.32M | $145K | $63K |
| Total Working Capital Change | $10.21M | $5K | $650K | -$12.69M | -$9.19M | $4.32M | $145K | $63K |
| Other Non-Cash Items | $521.26M | $3.87M | $67K | $6.42M | $3.19M | $782K | $576K | $1M |
| Net Cash from Operating | -$142.71M | -$99.66M | -$100.29M | -$85.14M | -$69.14M | -$36.29M | -$9.86M | -$2.66M |
| Investing Activities | ||||||||
| Capital Expenditures | -$941K | -$229K | -$1.07M | -$8.46M | -$3.89M | -$4.16M | -$748K | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$53.66M | -$9.91M | -$74.92M | -$123.19M | -$87.76M | $0 | $0 | $0 |
| Sales of Investments | $5M | $107M | $147M | $37.56M | $0 | $0 | $0 | $0 |
| Other Investing Activities | $799K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$48.8M | $96.86M | $71.01M | -$94.09M | -$91.65M | -$4.16M | -$748K | $0 |
| Financing Activities | ||||||||
| Debt Repaid | - | - | - | - | - | - | - | - |
| Common Stock Issuance | $505.13M | $55.83M | $4.58M | $115.97M | $189.2M | $0 | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$1.32M | -$2.43M | -$1.64M | $1.17M | -$1.66M | $259K | $7K | $0 |
| Net Cash from Financing | $503.81M | $53.39M | $2.94M | $117.14M | $232.91M | $82.53M | $17.7M | $2.46M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $312.29M | $50.59M | -$26.35M | -$62.09M | $72.12M | $42.07M | $7.1M | -$197K |
| Supplementary Data | ||||||||
| Operating Cash Flow | -$142.71M | -$99.66M | -$100.29M | -$85.14M | -$69.14M | -$36.29M | -$9.86M | -$2.66M |
| Capital Expenditure | -$941K | -$229K | -$1.07M | -$8.46M | -$3.89M | -$4.16M | -$748K | $0 |
| Free Cash Flow | -$143.65M | -$99.89M | -$101.36M | -$93.61M | -$73.04M | -$40.45M | -$10.6M | -$2.66M |
| Cash at Beginning | $84.36M | $33.77M | $60.12M | $122.21M | $50.1M | $8.03M | $929K | $1.13M |
| Cash at End | $396.65M | $84.36M | $33.77M | $60.12M | $122.21M | $50.1M | $8.03M | $929K |